Table 1

Characteristics of the study population

Autoimmune liver disordersUlcerative colitisDisease controlHealthy controls
No. (total n=201)39953022194337
Sex (F/M)9/3060/355/2510/128/1118/2513/24
Median age in years (range)54 (23–82)44 (26–83)41 (21–62)39 (26–69)47 (27–73)56 (36–78)37 (23–68)
Associated diseases
 Concomitant IBD (UC/CD)20 (13/7)1
 Concomitant PSC20
Presence of antibodies
 p-ANCA positive3995300130
 ‘Classical’ p-ANCAs1300120
 ‘Atypical’ p-ANCAs3892270000
 Median serum titre of p-ANCAs (≥1:10)3203202002020
 ANA positive (≥1:40)1264213111
 SMA positive (≥1:80)25600130
Treatment at time of testing
 Immunosuppressive drugs*09517
 5-Aminosalicylic acid18127
 Ursodeoxycholic acid3930
  • * Azathioprine and/or prednisolone/budesonide.

  • ANA, antinuclear antidody; c-ANCAs, cytoplasmic antineutrophil cytoplasmic antibodies; CD, Crohn's disease; F, female; IBD, inflammatory bowel diseases; M, male; p-ANCAs, perinuclear antineutrophil cytoplasmic antibodies; PSC, primary sclerosing cholangitis; SMA, smooth muscle actin; UC, ulcerative colitis.